Cytosorbents Corp. (CTSO) — Analysis Summary
Cytosorbents Corp. (CTSO) has a market cap of $22.62M with year-over-year revenue growth of +4.1%. Net margin stands at -22.1%. The stock trades at a P/E ratio of -1.9.
Key Takeaways
- Revenue changed +4.1% year-over-year
- Net margin of -22.1%
- P/E ratio of -1.9
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, CTSO posted revenue growth of +4.1% and trades at a P/E of -1.9.
Cytosorbents Corp. (CTSO)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
D/E at 7.7x — extreme leverage
Operating margin at -37.4% — material operating losses
Net margin at -31.9% — significant losses
Net income fell 44.5% vs the prior period.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
129
Headquarters
PRINCETON, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.